HR 1518 — New Era of Preventing End-Stage Kidney Disease Act
Congress 119 · introduced 2025-02-24
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
- Menendez, Robert (D, NJ-8) — cosponsor
- Lawler, Michael (R, NY-17) — cosponsor
- Davis, Donald G. (D, NC-1) — cosponsor
- Chu, Judy (D, CA-28) — cosponsor
- Castor, Kathy (D, FL-14) — cosponsor
- Miller, Carol D. (R, WV-1) — cosponsor
- Bishop, Sanford D. (D, GA-2) — cosponsor
- Lee, Susie (D, NV-3) — cosponsor
- Cuellar, Henry (D, TX-28) — cosponsor
Lobbied by (3)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
| Filing | Period | Registrant (lobbying firm) | Client | Income | Matched |
|---|---|---|---|---|---|
| 1st Quarter - Report | 2026 first_quarter | VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | — | H.R. 1518 |
| 1st Quarter - Report | 2026 first_quarter | OTSUKA AMERICA PHARMACEUTICAL, INC. | OTSUKA AMERICA PHARMACEUTICAL, INC. | — | H.R. 1518 |
| 1st Quarter - Report | 2026 first_quarter | NATIONAL KIDNEY FOUNDATION | NATIONAL KIDNEY FOUNDATION | — | H.R. 1518 |
Action timeline
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · Intro-H — Introduced in House
- · 1000 — Introduced in House
Text versions
- Introduced in House · 2025-02-24 — open
Connected on the graph
Inbound (12)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | Menendez, Robert | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Lawler, Michael | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Davis, Donald G. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Chu, Judy | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Miller, Carol D. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Castor, Kathy | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Cuellar, Henry | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Bishop, Sanford D. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Lee, Susie | cosponsor_of_bill | — | cosponsor | sponsorship |
| 2026-01-01 | NATIONAL KIDNEY FOUNDATION | lobbies_on_bill | — | H.R. 1518 | lobbying_bill_mention |
| 2026-01-01 | OTSUKA AMERICA PHARMACEUTICAL, INC. | lobbies_on_bill | — | H.R. 1518 | lobbying_bill_mention |
| 2026-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | lobbies_on_bill | — | H.R. 1518 | lobbying_bill_mention |
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Davis, Donald G. (D, house NC-1) | cosponsor | 3 | — | 4 |
| 2 | Bishop, Sanford D. (D, house GA-2) | cosponsor | 2 | — | 3 |
| 3 | Chu, Judy (D, house CA-28) | cosponsor | 2 | — | 3 |
| 4 | Castor, Kathy (D, house FL-14) | cosponsor | 1 | — | 2 |
| 5 | Lawler, Michael (R, house NY-17) | cosponsor | 1 | — | 2 |
| 6 | Cuellar, Henry (D, house TX-28) | cosponsor | 0 | — | 1 |
| 7 | Lee, Susie (D, house NV-3) | cosponsor | 0 | — | 1 |
| 8 | Menendez, Robert (D, house NJ-8) | cosponsor | 0 | — | 1 |
| 9 | Miller, Carol D. (R, house WV-1) | cosponsor | 0 | — | 1 |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | not employed | 0 | $0 | 73 | $59,151 | $59,151 |
| 2 | self employed | 0 | $0 | 19 | $17,066 | $17,066 |
| 3 | n/a | 0 | $0 | 16 | $7,575 | $7,575 |
| 4 | retired | 0 | $0 | 32 | $7,490 | $7,490 |
| 5 | dragonfly | 0 | $0 | 1 | $7,000 | $7,000 |
| 6 | castle harlan, inc. | 0 | $0 | 1 | $7,000 | $7,000 |
| 7 | openai | 0 | $0 | 2 | $4,999 | $4,999 |
| 8 | berenson partners, llc. | 0 | $0 | 1 | $3,643 | $3,643 |
| 9 | ohio machinery co. | 0 | $0 | 1 | $3,500 | $3,500 |
| 10 | thirdpoint llc | 0 | $0 | 1 | $3,500 | $3,500 |
| 11 | na | 0 | $0 | 1 | $3,500 | $3,500 |
| 12 | puma vineyards | 0 | $0 | 1 | $3,500 | $3,500 |
| 13 | solil management | 0 | $0 | 1 | $3,500 | $3,500 |
| 14 | method security | 0 | $0 | 1 | $3,500 | $3,500 |
| 15 | not employer | 0 | $0 | 2 | $3,400 | $3,400 |
| 16 | thorsen french advocacy | 0 | $0 | 2 | $3,000 | $3,000 |
| 17 | northwell health | 0 | $0 | 2 | $3,000 | $3,000 |
| 18 | lihui lo | 0 | $0 | 2 | $3,000 | $3,000 |
| 19 | self | 0 | $0 | 3 | $2,775 | $2,775 |
| 20 | basco | 0 | $0 | 1 | $2,500 | $2,500 |
| 21 | kathy fowler agency | 0 | $0 | 1 | $2,500 | $2,500 |
| 22 | apollo global management | 0 | $0 | 1 | $2,500 | $2,500 |
| 23 | hargrove crop insurance | 0 | $0 | 1 | $2,500 | $2,500 |
| 24 | united states hispanic business counci | 0 | $0 | 1 | $2,500 | $2,500 |
| 25 | disney | 0 | $0 | 3 | $2,250 | $2,250 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
9 predicted yes (2%) · 3 predicted no (1%) · 531 unknown (97%)
By party: · R: 2 yes / 0 no / 275 unknown · D: 7 yes / 0 no / 256 unknown · I: 0 yes / 3 no
9 high-confidence positions (voted + sponsor + cosponsor)
- Bishop, Sanford D. (D · house · GA-2) · cosponsor
- Castor, Kathy (D · house · FL-14) · cosponsor
- Chu, Judy (D · house · CA-28) · cosponsor
- Cuellar, Henry (D · house · TX-28) · cosponsor
- Davis, Donald G. (D · house · NC-1) · cosponsor
- Lawler, Michael (R · house · NY-17) · cosponsor
- Lee, Susie (D · house · NV-3) · cosponsor
- Menendez, Robert (D · house · NJ-8) · cosponsor
- Miller, Carol D. (R · house · WV-1) · cosponsor
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-17 · cosponsored by Bishop, Sanford D. (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Cuellar, Henry (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Lawler, Michael (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Chu, Judy (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Castor, Kathy (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Menendez, Robert (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Lee, Susie (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Miller, Carol D. (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Davis, Donald G. (cosponsor) · sponsorship
- 2026-01-01 · lobbied on by VERTEX PHARMACEUTICALS INCORPORATED (h.r. 1518) · lobbying_bill_mention
- 2026-01-01 · lobbied on by NATIONAL KIDNEY FOUNDATION (h.r. 1518) · lobbying_bill_mention
- 2026-01-01 · lobbied on by OTSUKA AMERICA PHARMACEUTICAL, INC. (h.r. 1518) · lobbying_bill_mention